-
AstraZeneca registers a Phase IIIb study of Capivasertib in China
According to the drug clinical trial registration and information publicity platform of the State Food and Drug Administration, AstraZeneca registered a phase IIIb study (CAPItrue) for advanced breas ... -
AstraZeneca IL-5R α monoclonal antibody approved for market in China
On August 19th, according to the official website of the National Medical Products Administration, AstraZeneca's IL-5R alpha monoclonal antibody (benralizumab) has been approved for listing in China. ... -
AstraZeneca China President Wang Lei, a legendary figure in the pharmaceutical industry, has been taken away to cooperate with the investigation
On the evening of October 30th local time, AstraZeneca, a multinational biopharmaceutical company jointly owned by the UK and Sweden, announced that Wang Lei, Global Executive Vice President, Interna ... -
21 Depth | Wang Lei and AstraZeneca's "Ten Years"
[Depth | "Ten Years" between Wang Lei and AstraZeneca] Since Wang Lei joined AstraZeneca China in 2013, the company has continuously strengthened its strategic layout in China and is committed to in- ... -
Will AstraZeneca, standing on the edge of an avalanche, become the next GSK?
Ten years ago, the "anti-corruption storm" in China caused a dramatic change for the British pharmaceutical company GlaxoSmithKline (GSK). Ten years later, another British pharmaceutical company, Ast ...